Koji Takiyama - Hisamitsu Pharmaceutical Sr Director

All Insiders . Germany . 
Stock . Hisamitsu Pharmaceutical Co . Stakeholders . Insider . Koji Takiyama
HPX Stock  EUR 24.80  0.40  1.59%   

Insider

Koji Takiyama is Sr Director of Hisamitsu Pharmaceutical Co
Age 52
Phone81 3 5293 1720
Webhttps://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0212 % which means that it generated a profit of $0.0212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0504 %, meaning that it generated $0.0504 on every $100 dollars invested by stockholders. Hisamitsu Pharmaceutical's management efficiency ratios could be used to measure how well Hisamitsu Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Hisamitsu Pharmaceutical Co has accumulated 219 M in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Hisamitsu Pharmaceutical has a current ratio of 7.26, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hisamitsu Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Hisamitsu Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hisamitsu Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hisamitsu to invest in growth at high rates of return. When we think about Hisamitsu Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Carl McMillianElanco Animal Health
51
Ramiro CabralElanco Animal Health
51
Zhang ChunboGuangzhou Baiyunshan Pharmaceut
46
Yan LiHANSOH PHARMAC HD 00001
N/A
Sheung ChanHANSOH PHARMAC HD 00001
65
Andrew PlumpTakeda Pharmaceutical
58
ShouBai ChaoCanSino Biologics
60
David RicksElanco Animal Health
50
Mitsuru NakataTsumura Co
N/A
Kimitoshi UsuiTsumura Co
N/A
Jianxiong ZhengGuangzhou Baiyunshan Pharmaceut
53
Tao ZhuCanSino Biologics
49
Chunhua ZhongHANSOH PHARMAC HD 00001
44
Qiang XuCanSino Biologics
50
Dean LiMerck Company
N/A
Chris KeeleyElanco Animal Health
N/A
Jing WangCanSino Biologics
42
Dirk ToepferMerck Company
N/A
Gabriele RicciTakeda Pharmaceutical
45
Jianzhong LiuCanSino Biologics
55
Friederike RotschMerck Company
51
Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals in Japan. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. HISAMITSU PHARMA operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2770 people. Hisamitsu Pharmaceutical Co (HPX) is traded on Frankfurt Exchange in Germany and employs 2,784 people.

Management Performance

Return On Equity0.0504
Return On Asset0.0212

Hisamitsu Pharmaceutical Leadership Team

Elected by the shareholders, the Hisamitsu Pharmaceutical's board of directors comprises two types of representatives: Hisamitsu Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hisamitsu. The board's role is to monitor Hisamitsu Pharmaceutical's management team and ensure that shareholders' interests are well served. Hisamitsu Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hisamitsu Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kyu Saito, Head Officer
Shinichiro Takao, Head MD
Mitsutoshi Tsuruta, Ex Division
Masaya Okuno, OTC Division
Kazuhide Nakatomi, CEO Pres
Koji Takiyama, Sr Director
Kosuke Sugiyama, Exec MD
Shinichi Murayama, Exec Director
Nobuo Tsutsumi, Mgmt Dept
Mitsumasa Kabashima, Pres Ltd

Hisamitsu Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hisamitsu Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0504
Return On Asset0.0212
Profit Margin0.10 %
Operating Margin0.09 %
Current Valuation1.09 B
Shares Outstanding79.53 M
Shares Owned By Insiders26.45 %
Shares Owned By Institutions35.29 %
Price To Earning34.35 X
Price To Book1.14 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Hisamitsu Stock

Hisamitsu Pharmaceutical financial ratios help investors to determine whether Hisamitsu Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hisamitsu with respect to the benefits of owning Hisamitsu Pharmaceutical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY